1921
Volume 98, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Miltefosine is the only orally administrable drug for the treatment of leishmaniasis. But in recent years, a decline in its efficacy points toward the emergence of resistance to this drug. Knowledge of biomarkers for miltefosine resistance may be beneficial for proper selection of treatment regimen. Splenic aspirates were collected and parasites cultured from patients relapsed after initial cure ( = 15) and successfully treated ( = 15) with miltefosine. Differential expression of genes in miltefosine-resistant strains was examined by DNA microarray and validated by real-time reverse transcription polymerase chain reaction and Western blotting. Of 669 upregulated genes, the cysteine protease-like protein of calpain family (GenBank: CBZ34784) was found to be significantly overexpressed in resistant parasite strains and only anti-calpain antibodies showed its presence in the sera of relapse patients through Western blotting. Calpain family cysteine protease-like protein can be useful as a potential biomarker of miltefosine unresponsiveness.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.16-0983
2017-12-26
2019-11-13
Loading full text...

Full text loading...

/deliver/fulltext/14761645/98/2/tpmd160983.html?itemId=/content/journals/10.4269/ajtmh.16-0983&mimeType=html&fmt=ahah

References

  1. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, Kumar PC, Murray HW, , 2000. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 31: 11041107. [Google Scholar]
  2. WHO, 2005. Regional Strategic Framework for Elimination of Kala-azar from the South-East Asia Region (2005–2015). New Delhi: Regional Office for South-East Asia SEA-VBC-85 (Rev-1). Geneva, Switzerland: World Health Organization.
  3. Sundar S, Olliaro PL, , 2007. Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management. Ther Clin Risk Manag 3: 733740. [Google Scholar]
  4. Sundar S, Singh A, Rai M, Prajapati VK, Singh AK, Ostyn B, Boelaert M, Dujardin JC, Chakravarty J, , 2012. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis 55: 543550. [Google Scholar]
  5. Hefnawy A, Berg M, Dujardin JC, De Muylder G, , 2016. Exploiting knowledge on Leishmania drug resistance to support the quest for new drugs. Trends Parasitol 33: 162174. [Google Scholar]
  6. Downing T, 2011. Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance. Genome Res 21: 21432156. [Google Scholar]
  7. Edgar R, Domrachev M, Lash AE, , 2002. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207210. [Google Scholar]
  8. Deborggraeve S, Boelaert M, Rijal S, De Doncker S, Dujardin JC, Herdewijn P, Buscher P, , 2008. Diagnostic accuracy of a new Leishmania PCR for clinical visceral leishmaniasis in Nepal and its role in diagnosis of disease. Trop Med Int Health 13: 13781383. [Google Scholar]
  9. Livak KJ, Schmittgen TD, , 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402408. [Google Scholar]
  10. Kumar D, Tiwary P, Dube A, Chakravarty J, Rai M, Sundar S, , 2013. Cloning, expression and purification of L. donovani specific antigen for serodiagnosis of visceral leishmaniasis. J Mol Biomark Diagn 4: 1000141. [Google Scholar]
  11. Rijal S, 2013. Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clin Infect Dis 56: 15301538. [Google Scholar]
  12. Rahman M, 2011. Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh. Am J Trop Med Hyg 85: 6669. [Google Scholar]
  13. Biomarkers Definitions Working Group, 2001. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69: 8995. [Google Scholar]
  14. Hertz-Fowler C, Ersfeld K, Gull K, , 2001. CAP5.5, a life-cycle-regulated, cytoskeleton-associated protein is a member of a novel family of calpain-related proteins in Trypanosoma brucei. Mol Biochem Parasitol 116: 2534. [Google Scholar]
  15. Frame MJ, Mottram JC, Coombs GH, , 2000. Analysis of the roles of cysteine proteinases of Leishmania mexicana in the host-parasite interaction. Parasitology 121: 367377. [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.16-0983
Loading
/content/journals/10.4269/ajtmh.16-0983
Loading

Data & Media loading...

  • Received : 15 Dec 2016
  • Accepted : 26 Sep 2017
  • Published online : 26 Dec 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error